Centessa Pharmaceuticals plc (NASDAQ:CNTA) Receives $25.17 Consensus Price Target from Analysts

Centessa Pharmaceuticals plc (NASDAQ:CNTA) has been assigned an average recommendation of “Buy” from the six research firms that are currently covering the stock, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy rating. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $25.17.

A number of research firms have recently weighed in on CNTA. Morgan Stanley upgraded shares of Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $11.00 to $26.00 in a report on Thursday, September 19th. Oppenheimer reaffirmed an “outperform” rating and set a $14.00 price target on shares of Centessa Pharmaceuticals in a research report on Wednesday, August 14th. Guggenheim boosted their target price on Centessa Pharmaceuticals from $20.00 to $24.00 and gave the stock a “buy” rating in a research note on Wednesday, September 11th. B. Riley assumed coverage on Centessa Pharmaceuticals in a research note on Thursday, September 19th. They issued a “buy” rating and a $33.00 price target for the company. Finally, BMO Capital Markets boosted their price target on Centessa Pharmaceuticals from $20.00 to $35.00 and gave the stock an “outperform” rating in a research note on Monday, September 16th.

Centessa Pharmaceuticals Stock Performance

Shares of CNTA stock opened at $16.50 on Friday. The company’s 50 day moving average is $15.61 and its 200 day moving average is $11.88. The company has a quick ratio of 13.29, a current ratio of 13.29 and a debt-to-equity ratio of 0.27. The firm has a market cap of $1.87 billion, a price-to-earnings ratio of -10.58 and a beta of 1.47. Centessa Pharmaceuticals has a 52-week low of $5.58 and a 52-week high of $17.59.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.02). On average, sell-side analysts anticipate that Centessa Pharmaceuticals will post -1.68 EPS for the current fiscal year.

Insider Transactions at Centessa Pharmaceuticals

In related news, CEO Saurabh Saha sold 4,169 shares of the stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $12.32, for a total value of $51,362.08. Following the transaction, the chief executive officer now owns 827,755 shares in the company, valued at approximately $10,197,941.60. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, insider Gregory M. Weinhoff sold 25,000 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $15.00, for a total transaction of $375,000.00. Following the completion of the transaction, the insider now directly owns 223,369 shares in the company, valued at approximately $3,350,535. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Saurabh Saha sold 4,169 shares of the company’s stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $12.32, for a total value of $51,362.08. Following the completion of the sale, the chief executive officer now owns 827,755 shares in the company, valued at approximately $10,197,941.60. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 325,031 shares of company stock worth $5,213,043 over the last three months. 11.59% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Several large investors have recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Centessa Pharmaceuticals by 47.7% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock worth $40,000 after acquiring an additional 826 shares during the period. Atria Investments Inc grew its holdings in Centessa Pharmaceuticals by 7.0% in the third quarter. Atria Investments Inc now owns 17,134 shares of the company’s stock valued at $274,000 after purchasing an additional 1,116 shares during the period. GAMMA Investing LLC increased its position in shares of Centessa Pharmaceuticals by 103.1% in the third quarter. GAMMA Investing LLC now owns 2,972 shares of the company’s stock valued at $48,000 after buying an additional 1,509 shares in the last quarter. Quarry LP raised its stake in shares of Centessa Pharmaceuticals by 47.8% during the 2nd quarter. Quarry LP now owns 9,608 shares of the company’s stock worth $87,000 after buying an additional 3,108 shares during the period. Finally, China Universal Asset Management Co. Ltd. lifted its position in shares of Centessa Pharmaceuticals by 99.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,593 shares of the company’s stock valued at $217,000 after buying an additional 6,785 shares in the last quarter. 82.01% of the stock is currently owned by institutional investors and hedge funds.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.